MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./320/0.1/21.03.25 Stock

Warrant

DE000MG0Y1P4

Market Closed - Börse Stuttgart 14:52:26 2024-05-15 EDT
0.185 EUR +5.11% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./320/0.1/21.03.25
Current month-26.67%
1 month-37.14%
Date Price Change
24-05-15 0.185 +5.11%
24-05-14 0.176 -3.30%
24-05-13 0.182 +5.81%
24-05-10 0.172 -25.22%
24-05-09 0.23 -4.17%

Delayed Quote Börse Stuttgart

Last update May 15, 2024 at 02:52 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0Y1P
ISINDE000MG0Y1P4
Date issued 2024-03-27
Strike 320 $
Maturity 2025-03-21 (310 Days)
Parity 10 : 1
Emission price 0.24
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.39
Lowest since issue 0.16
Spread 0.031
Spread %14.35%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
235 USD
Average target price
278.8 USD
Spread / Average Target
+18.65%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW